Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV9103 in hormone refractory prostate cancer
NCT00831467Phase 2Completed
- Sponsor
- CureVac
- Start
- Jan 2009
- Primary completion
- Dec 2009
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of CV9103 in prostate cancer (PCa), sponsored by CureVac. Started Jan 2009; status: completed.
02
Drugs
CV9103
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00831467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00831467.